首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1319136

全球缺氧治療市場 - 2023-2030 年

Global Hypoxia Treatment Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球缺氧治療市場規模在2022 年達到7760 萬美元，預計到2030 年將達到1.343 億美元，2023-2030 年的年複合成長率為7.2%。缺氧狀況的日益普遍、技術的不斷進步、臨床試驗的不斷增加、消費者需求的不斷成長以及美國食品和藥物管理局批准數量的不斷增加等因素都可能推動缺氧治療市場的發展。

缺氧與多種生物過程有關，包括病原微生物感染、癌症、急性和慢性疾病以及許多其他應激反應。低氧誘導因子（HIFs）能感知低氧，從而調節一系列下游基因的表達，這些基因參與了細胞代謝、細胞死亡、細胞增殖、糖酵解、免疫反應、微生物感染和轉移等多個過程。

市場動態

缺氧治療技術的不斷進步有望推動全球市場成長

由於各種技術進步，缺氧治療市場出現了顯著成長。許多關鍵企業通過推出新產品和服務在這些進步中發揮了重要作用。新產品或服務可以提高診斷或醫療設備的生產率和功效。

例如，2023 年6 月20 日，Akebia Therapeutics 公司宣布瑞士治療產品機構批准Vafseo（伐杜司他）上市，這是一種口服缺氧誘導因子脯氨酰羥化酶（HIF-PH）抑製劑，用於治療慢性維持性透析成人慢性腎病（CKD）相關症狀性貧血。

瑞士醫藥公司批准Vafseo 的依據是包括7500 多名患者在內的開發項目數據，其中包括vadadustat 用於治療成年透析患者CKD 引起的貧血的全球3 期臨床項目。因此，由於上述因素，該市場有望在預測期內得到推動。

美國食品及藥物管理局對缺氧病症的批准不斷增加，有望推動全球缺氧治療市場的發展

FDA 批准治療哮喘、慢性阻塞性肺病和肺炎等缺氧病症的數量不斷增加，成為市場成長的主要驅動力。此外，許多關鍵企業通過推出新產品和服務，在推動市場發展方面發揮了重要作用。

例如，2021 年8 月13 日，默克公司宣布一種口服低氧誘導因子-2 α（HIF-2α）抑製劑WELIREG 獲得FDA 批准，用於治療患有Von Hippel-Lindau (VHL)病且需要治療相關腎細胞癌、中樞神經系統血管母細胞瘤或胰腺神經內分泌腫瘤的成年患者。

此外，2022 年3 月15 日，美國食品和藥物管理局（FDA）批准了首個Symbicort 吸入氣霧劑學名藥，用於治療兩種常見的肺部疾病，即6 歲及以上患者的哮喘，以及慢性阻塞性肺病（COPD）（包括慢性支氣管炎）患者的氣流阻塞維持治療和減少病情惡化。這種複雜的非專利藥物-器械組合產品不用於治療哮喘急性發作。因此，由於上述因素，市場有望在預測期內得到推動。

對慢性阻塞性肺病等缺氧疾病缺乏認知預計將阻礙全球缺氧治療市場的成長

據Dove Press 稱，為了解慢性阻塞性肺病在沙烏地阿拉伯Aseer 地區的發病率，進行了流行病學研究。該地區居民對慢性阻塞性肺病的認知度很低。只有34.0% 的人正確了解戒菸對預防慢性阻塞性肺病的重要作用。這項研究表明，迫切需要提高普通人群對慢性阻塞性肺病及其風險因素的認知。應在課程中加強這一主題，並在公共活動和研討會中進行討論。此外，還需要在全國範圍內開展研究，以幫助政策制定者實施適當的預防和治療策略，促進人口的肺部健康。

COVID-19 影響分析

COVID-19 大流行對缺氧治療市場產生了重大影響。大流行期間，許多醫療系統不堪重負，非緊急醫療程序和篩查被推遲或取消。這導致患者缺氧狀況的診斷和開始治療的時間被推遲。因此，一些缺氧症病例在後期才得到診斷，可能會影響治療效果。

臨床試驗對於開發新的治療方法和改善缺氧治療市場的療效至關重要。然而，大流行病擾亂了臨床試驗的進行，許多研究機構暫時停止招生或修改方案，將患者安全放在首位。這導致了試驗完成和新療法上市的延遲。

此外，大流行期間研發工作的重點也發生了轉移，主要集中在開發COVID-19 的疫苗和治療方法上。資源和注意力的轉移可能暫時影響了缺氧相關研發活動的進展。

此外，為了最大限度地降低COVID-19 傳播的風險，醫療服務提供者對治療方法進行了調整，如減少親自出診、增加遠程醫療諮詢和修改治療時間表。這些變化影響了患者的整體體驗和缺氧治療市場的管理。

俄烏衝突分析

俄烏衝突對兩國生活的各個方面都產生了重大影響，包括醫療保健和缺氧性疾病（如哮喘和慢性阻塞性肺病）的管理。衝突導致受影響地區的醫療基礎設施遭到破壞和中斷。包括醫院和診所在內的醫療設施可能遭到破壞或無法進入，這使得缺氧性疾病患者難以獲得適當的診斷、治療和後續護理。

衝突可能導致醫療資源供應有限，包括醫療設備、藥品和專業醫護人員。這種匱乏可能導致缺氧性疾病患者的診斷延誤、治療方案不足和疾病管理不理想。

衝突導致人口流離失所，人們被迫離開家園，到更安全的地區避難。這種流離失所現象可能會擾亂患者接受治療的連續性，因為他們可能難以獲得固定的醫療服務提供者和治療機構的幫助，從而可能導致慢性疼痛疾病治療的中斷。

此外，衝突及其後果可能會阻礙受影響地區與缺氧性疾病有關的數據收集和研究工作。這可能會影響最新流行病學數據的可用性，阻礙臨床試驗，並限制對受衝突影響地區缺氧治療結果的了解。因此，考慮到上述因素，缺氧治療市場受到俄羅斯和烏克蘭衝突的影響不大。

Market Overview

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030. Factors such as the increasing prevalence of hypoxia conditions, continuous advancements in technology, rising clinical trials, increasing consumer demand, and growing FDA approvals are likely to boost the hypoxia treatment market.

Hypoxia is linked to several biological processes which include pathogenic microbe infection, cancers, acute and chronic diseases, and many other stress responses. Hypoxia-inducible factors (HIFs) sense hypoxia to regulate the expressions of a series of downstream genes expression, which participate in multiple processes including cell metabolism, cell death, cell proliferation, glycolysis, immune response, microbe infection, and metastasis.

Market Dynamics

Rising Technological Advancements in Hypoxia Treatment are Expected to Boost the Global Market Growth

The hypoxia treatment market has witnessed significant growth due to various technological advancements. Many key players play a major role in these advancements by launching new products and services. This new product or service can rise the productivity and efficacy of the diagnostic or medical device.

For instance, on June 20, 2023, Akebia Therapeutics, Inc. announced that the Swiss agency for therapeutic products granted marketing authorization for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

The Swissmedic approval of Vafseo is based on data from a development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Rising FDA Approvals for Hypoxia Conditions are Expected to Boost the Global Hypoxia Treatment Market

The increasing FDA approvals for hypoxia conditions such as asthma, COPD, and pneumonia act as a major driver for the market growth. Also, many key players play a major role in the advancements of the market by launching new products and services.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

Additionally, on March 15, 2022, the U.S. Food and Drug Administration (FDA) approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions that is asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis. This complex generic drug-device combination product, are not used to treat acute asthma attacks. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Lack of Awareness Associated with Hypoxia Conditions such as COPD is Expected to Hamper Global Hypoxia Treatment Market Growth

According to Dove Press, epidemiological studies were conducted to access the prevalence of COPD in the Aseer region of Saudi Arabia. The awareness regarding the COPD condition was low among the people of the region. Only 34.0% correctly knew that quitting smoking has an important role in preventing COPD. This study needs an urgent need of improving awareness of COPD and its risk factors in the general population. This subject should be strengthened in the curriculum and discussed in public campaigns and seminars. Furthermore, nationwide study is required to help the policymakers for implementing suitable preventive and curative strategies to promote the pulmonary health of the population.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hypoxia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of hypoxia conditions and initiation of treatment for patients. As a result, some hypoxia disease cases were diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in the hypoxia treatment market. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of hypoxia related research and development activities.

Also, to minimize the risk of COVID-19 transmission, healthcare providers implemented changes in treatment delivery, such as reducing in-person clinic visits, increasing telemedicine consultations, and modifying treatment schedules. These changes have impacted the overall patient experience and the management of the hypoxia treatment market.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of hypoxic diseases such as asthma and COPD. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with hypoxic diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for hypoxic disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

Furthermore, the conflict and its aftermath may hinder data collection and research efforts related to hypoxic diseases in the affected regions. This can impact the availability of up-to-date epidemiological data, hinder clinical trials, and limit the understanding of hypoxic treatment outcomes in conflict-affected areas. Therefore, considering the above factors, the hypoxic treatment market has been moderately affected by the conflict between Russia and Ukraine.

Segment Analysis

The global hypoxia treatment market is segmented based on type, disease type, end users, and region.

Owing to Rising Clinical Trials, the Hypoxic Hypoxia Segment Accounted for Approximately 48.6% of the Hypoxia Treatment Market Share

According to ClinicalTrials.gov, on April 25, 2023, Capital Medical University conducted a clinical trial on an exploratory study of intermittent hypoxia treatment in chronic cerebral hypoperfusion. This interventional study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion. This study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the use of chronic cerebral hypoperfusion. The estimated study completion date is Oct 10, 2023.

Additionally, On Feb 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has received the US Food and Drug Administration (FDA), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for four months. Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral and convenient option for patients in the US with anemia of CKD on dialysis. Thus, owing to the above factors, the CMOS segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure

The North American region is anticipated to experience growth in the field of hypoxia treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in hypoxia treatment throughout the forecast period.

WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.

Competitive Landscape

The major global players in the market include: CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

Why Purchase the Report?

To visualize the global hypoxia treatment market segmentation based on the type, disease type, end users, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of hypoxia treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global hypoxia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Disease Type
3.3. Snippet by End Users
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising FDA Approvals for Hypoxia Conditions
  - 4.1.1.2. Increasing Clinical Trials for Hypoxia Conditions
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Awareness Associated with Hypoxia Conditions
- 4.1.3. Opportunity
  - 4.1.3.1. Emerging market of Hypoxia treatment
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
8.2. Hypoxic Hypoxia*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hypemic Hypoxic
8.4. Histotoxic Hypoxia
8.5. Stagnant Hypoxia

9. By Disease Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.1.2. Market Attractiveness Index, By Disease Type
9.2. Asthma*
9.3. Chronic Obstructive Pulmonary Disease (COPD)
9.4. Pneumonia
9.5. Others

10. By End Users

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
10.1.2. Market Attractiveness Index, By End Users

10.2. Hospitals
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. CASI Pharmaceuticals Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Aileron Therapeutics, Inc., LLC.
13.3. Lupin Pharmaceuticals, Inc.
13.4. PharmaShots
13.5. Hancock Medical Inc.
13.6. Hamilton Company
13.7. Spotlight Labs
13.8. GlaxoSmithKline plc
13.9. Sun Pharmaceutical Industries Ltd.
13.10. Merck & Co.

LIST NOT EXHAUSTIVE